Capital Group Investment Management PTE. LTD. Takes $497,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)

Capital Group Investment Management PTE. LTD. purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 3,609 shares of the biotechnology company's stock, valued at approximately $497,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Public Employees Retirement System of Ohio purchased a new stake in Ascendis Pharma A/S in the third quarter worth approximately $1,101,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at $30,000. Exome Asset Management LLC lifted its holdings in Ascendis Pharma A/S by 119.2% in the 3rd quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company's stock worth $6,547,000 after purchasing an additional 23,849 shares in the last quarter. GAMMA Investing LLC increased its holdings in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares during the last quarter. Finally, Diversified Trust Co boosted its stake in Ascendis Pharma A/S by 7.4% during the fourth quarter. Diversified Trust Co now owns 45,038 shares of the biotechnology company's stock valued at $6,200,000 after buying an additional 3,114 shares during the last quarter.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock traded down $3.90 during trading on Monday, reaching $161.15. 691,086 shares of the company were exchanged, compared to its average volume of 482,623. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37. The stock's 50 day simple moving average is $152.00 and its two-hundred day simple moving average is $138.12. The company has a market capitalization of $9.83 billion, a P/E ratio of -22.70 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.64. As a group, equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Cantor Fitzgerald increased their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, February 25th. Evercore ISI lifted their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, February 18th. The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a report on Tuesday, February 18th. Finally, Royal Bank of Canada initiated coverage on shares of Ascendis Pharma A/S in a research note on Wednesday, April 16th. They set an "outperform" rating and a $205.00 price objective for the company. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $204.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.